胆汁游离DNA二代测序用于恶性胆道狭窄早期检测
这项前瞻性队列研究纳入68例疑似胆道狭窄患者,比较首次ERCP时胆汁游离DNA的NGS突变分析(Bilemut)与初始病理诊断的表现。Bilemut检测恶性的敏感度和特异度分别为96.4%和69.2%,在初始诊断为良性或不确定的患者中敏感度达100%。
要点
- Bilemut检测胆道恶性狭窄的敏感度96.4%、特异度69.2%。
- 初始良性或不确定狭窄患者中Bilemut敏感度达100%。
- Bilemut在初始诊断阶段可提高恶性检出并减少管理延迟。
核心结论
- 在胆道狭窄初始诊断阶段实施Bilemut可显著提高恶性检出、减少临床管理延迟并辅助靶向治疗患者筛选。
研究设计与样本
- 前瞻性队列研究纳入68例疑似胆道狭窄患者,于首次ERCP时采集胆汁,使用Oncomine Pan-Cancer Cell-Free assay进行NGS突变分析。
主要发现
- 初始病理诊断将狭窄分为良性26例、不确定9例、恶性33例,其敏感度和特异度分别为60%和100%。
- 随访中26例初始良性狭窄有14例、9例初始不确定狭窄有8例最终为恶性。
- Bilemut检测恶性的敏感度和特异度分别为96.4%和69.2%。
- 4例Bilemut假阳性中1例在延长随访后发生胰腺癌。
- 初始诊断为良性或不确定狭窄的患者中Bilemut对恶性的敏感度为100%。
临床怎么用
- 对疑似胆道狭窄患者,可在首次ERCP采集胆汁行Bilemut检测以辅助恶性早期识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite significant progresses in imaging and pathological evaluation, early differentiation between benign and malignant biliary strictures remains challenging. Endoscopic retrograde cholangiopancreatography (ERCP) is used to investigate biliary strictures, enabling the collection of bile. We tested the diagnostic potential of next-generation sequencing (NGS) mutational analysis of bile cell-free DNA (cfDNA). DESIGN: A prospective cohort of patients with suspicious biliary strictures (n=68) was studied. The performance of initial pathological diagnosis was compared with that of the mutational analysis of bile cfDNA collected at the time of first ERCP using an NGS panel open to clinical laboratory implementation, the Oncomine Pan-Cancer Cell-Free assay. RESULTS: An initial pathological diagnosis classified these strictures as of benign (n=26), indeterminate (n=9) or malignant (n=33) origin. Sensitivity and specificity of this diagnosis were 60% and 100%, respectively, as on follow-up 14 of the 26 and eight of the nine initially benign or indeterminate strictures resulted malignant. Sensitivity and specificity for malignancy of our NGS assay, herein named Bilemut, were 96.4% and 69.2%, respectively. Importantly, one of the four Bilemut false positives developed pancreatic cancer after extended follow-up. Remarkably, the sensitivity for malignancy of Bilemut was 100% in patients with an initial diagnosis of benign or indeterminate strictures. Analysis of 30 paired bile and tissue samples also demonstrated the superior performance of Bilemut. CONCLUSION: Implementation of Bilemut at the initial diagnostic stage for biliary strictures can significantly improve detection of malignancy, reduce delays in the clinical management of patients and assist in selecting patients for targeted therapies.
引用
- Arechederra M, Rullán M, Amat I, et al. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut. 2021. PMID: 34285068. doi:10.1136/gutjnl-2021-325178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。